These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

898 related items for PubMed ID: 28285695

  • 1. Optimal management of ALK-positive NSCLC progressing on crizotinib.
    Metro G, Tazza M, Matocci R, Chiari R, Crinò L.
    Lung Cancer; 2017 Apr; 106():58-66. PubMed ID: 28285695
    [Abstract] [Full Text] [Related]

  • 2. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.
    Dudnik E, Siegal T, Zach L, Allen AM, Flex D, Yust-Katz S, Limon D, Hirsch FR, Peled N.
    J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785
    [Abstract] [Full Text] [Related]

  • 3. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES, Barlesi F, Mok T, Ahn MJ, Shen J, Zhang P, Ou SI.
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [Abstract] [Full Text] [Related]

  • 4. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
    Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, Ning Y, Wardwell SD, Miller D, Song Y, Eichinger L, Moran L, Huang WS, Liu S, Zou D, Wang Y, Mohemmad Q, Jang HG, Ye E, Narasimhan N, Wang F, Miret J, Zhu X, Clackson T, Dalgarno D, Shakespeare WC, Rivera VM.
    Clin Cancer Res; 2016 Nov 15; 22(22):5527-5538. PubMed ID: 27780853
    [Abstract] [Full Text] [Related]

  • 5. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
    Lin YT, Yu CJ, Yang JC, Shih JY.
    Clin Lung Cancer; 2016 Sep 15; 17(5):e77-e94. PubMed ID: 27130468
    [Abstract] [Full Text] [Related]

  • 6. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
    Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, Iafrate AJ, Takeuchi K, Taiji M, Okuno Y, Fujita N, Engelman JA, Shaw AT.
    Clin Cancer Res; 2014 Nov 15; 20(22):5686-96. PubMed ID: 25228534
    [Abstract] [Full Text] [Related]

  • 7. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
    Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW.
    J Clin Oncol; 2016 Mar 01; 34(7):661-8. PubMed ID: 26598747
    [Abstract] [Full Text] [Related]

  • 8. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
    Muller IB, De Langen AJ, Honeywell RJ, Giovannetti E, Peters GJ.
    Expert Rev Anticancer Ther; 2016 Mar 01; 16(2):147-57. PubMed ID: 26654422
    [Abstract] [Full Text] [Related]

  • 9. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N, Santarpia M, Gonzalez Cao M, Teixido C, Sosa AE, Berenguer J, Rodriguez Capote A, Altavilla G, Rosell R.
    Expert Opin Investig Drugs; 2017 Jun 01; 26(6):713-722. PubMed ID: 28463570
    [Abstract] [Full Text] [Related]

  • 10. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K, Kolesar JM.
    Am J Health Syst Pharm; 2015 Sep 01; 72(17):1456-62. PubMed ID: 26294238
    [Abstract] [Full Text] [Related]

  • 11. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A.
    Expert Rev Clin Pharmacol; 2016 Aug 01; 9(8):1005-13. PubMed ID: 27232673
    [Abstract] [Full Text] [Related]

  • 12. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep 01; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 13. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y, Yamamoto N, Masters ET, Kikkawa H, Mardekian J, Wiltshire R, Togo K, Ohe Y.
    Adv Ther; 2020 Jul 01; 37(7):3311-3323. PubMed ID: 32472430
    [Abstract] [Full Text] [Related]

  • 14. Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure.
    Oya Y, Yoshida T, Kuroda H, Shimizu J, Horio Y, Sakao Y, Hida T, Yatabe Y.
    Anticancer Res; 2017 Nov 01; 37(11):6477-6480. PubMed ID: 29061835
    [Abstract] [Full Text] [Related]

  • 15. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
    Toyokawa G, Seto T, Takenoyama M, Ichinose Y.
    Cancer Metastasis Rev; 2015 Dec 01; 34(4):797-805. PubMed ID: 26342831
    [Abstract] [Full Text] [Related]

  • 16. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
    Zhao Y, Zhang B, Wang S, Qiao R, Xu J, Zhang L, Zhang Y, Han B.
    Clin Lung Cancer; 2019 Nov 01; 20(6):e631-e637. PubMed ID: 31362880
    [Abstract] [Full Text] [Related]

  • 17. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR.
    Lancet Oncol; 2016 Dec 01; 17(12):1683-1696. PubMed ID: 27836716
    [Abstract] [Full Text] [Related]

  • 18. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S, Hayashi H, Okamoto K, Fujiwara K, Hasegawa Y, Kaneda H, Tanaka K, Takeda M, Nakagawa K.
    Clin Lung Cancer; 2016 Nov 01; 17(6):528-534. PubMed ID: 27318655
    [Abstract] [Full Text] [Related]

  • 19. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM.
    Cancer Treat Rev; 2017 Apr 01; 55():181-189. PubMed ID: 28427013
    [Abstract] [Full Text] [Related]

  • 20. Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.
    Ricciuti B, De Giglio A, Mecca C, Arcuri C, Marini S, Metro G, Baglivo S, Sidoni A, Bellezza G, Crinò L, Chiari R.
    Med Oncol; 2018 Apr 17; 35(5):72. PubMed ID: 29666949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.